EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy

Lorin Begré iD, Anders Boyd iD, Marie-Laure Plissonnier iD, Barbara Testoni iD, Luisa Salazar-Vizcaya iD, Franziska Suter-Riniker iD, Caroline Scholtès iD, Charles Béguelin iD, Jürgen K Rockstroh iD, Huldrych F Günthard iD, Alexandra Calmy iD, Matthias Cavassini iD und 8 weitere

The Journal of Infectious Diseases · 2024

DOI: 10.1093/infdis/jiae189 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2024. Verfasst von Lorin Begré und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland. Hauptthemen laut MEDLINE: Tenofovir, HIV Infections, Hepatitis B Surface Antigens, RNA, Viral. Die Arbeit nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gilead Sciences, NEAT-ID Foundation, Department of Teaching and Research, Inselspital, Bern University Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

We evaluated long-term trajectories of circulating hepatitis B virus (HBV) RNA and hepatitis B core–related antigen (HBcrAg) in persons with and without hepatitis B surface antigen (HBsAg) loss during tenofovir therapy in the Swiss HIV Cohort Study.

Methods

We included 29 persons with HIV with HBsAg loss and 29 matched persons with HIV without HBsAg loss. We compared HBV RNA and HBcrAg decline and assessed the cumulative proportions with undetectable HBV RNA and HBcrAg levels during tenofovir therapy using Kaplan-Meier estimates.

Results

HBsAg loss occurred after a median of 4 years (IQR, 1–8). All participants with HBsAg loss achieved suppressed HBV DNA and undetectable HBV RNA preceding undetectable quantitative HBsAg levels, whereas 79% achieved negative HBcrAg. In comparison, 79% of participants without HBsAg loss achieved undetectable HBV-RNA and 48% negative HBcrAg. After 2 years of tenofovir therapy, an HBV RNA decline ≥1 log10 copies/mL had 100% sensitivity and 36.4% specificity for HBsAg loss, whereas an HBcrAg decline ≥1 log10 U/mL had 91.0% sensitivity and 64.5% specificity.

Conclusions

HBV RNA suppression preceded undetectable quantitative HBsAg levels and had high sensitivity but low specificity for HBsAg loss during tenofovir therapy in persons with HIV. HBcrAg remained detectable in approximately 20% of persons with HBsAg loss and 50% of persons without HBsAg loss.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHIV InfectionsHepatitis B Surface AntigensRNA, ViralHepatitis B virusHepatitis B Core AntigensCoinfectionHumansMaleFemaleAdultMiddle AgedHepatitis BAnti-HIV AgentsCohort StudiesSwitzerlandViral LoadHepatitis B, ChronicDNA, Viral

Stichwörter der Autor:innen

HBV RNAHIVhepatitis B core–related antigenhepatitis B viruskinetics

Substanzen

TenofovirHepatitis B Surface AntigensRNA, ViralHepatitis B Core AntigensAnti-HIV AgentsDNA, Viral

Autor:innen und Institutionen

  • Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Switzerland.
  • Graduate School for Health Sciences, University of Bern, Switzerland.
  • Department of Infectious Diseases, Research and Prevention, Public Health Service of Amsterdam, The Netherlands.
  • Stichting hiv monitoring Amsterdam, The Netherlands.
  • Department of Infectious Diseases, Amsterdam UMC location University of Amsterdam, The Netherlands.
  • Department of Infectious Diseases, Amsterdam Institute for Infection and Immunity, The Netherlands.

ORCID-Profile: Lorin Begré, Anders Boyd, Marie-Laure Plissonnier, Barbara Testoni, Luisa Salazar-Vizcaya, Franziska Suter-Riniker, Caroline Scholtès, Charles Béguelin, Jürgen K Rockstroh, Huldrych F Günthard, Alexandra Calmy, Matthias Cavassini, Hans H Hirsch, Patrick Schmid, Enos Bernasconi, Massimo Levrero, Gilles Wandeler, Fabien Zoulim, Andri Rauch

Förderung

  • Gilead Sciences
  • NEAT-ID Foundation
  • Department of Teaching and Research, Inselspital, Bern University Hospital
  • Liquid Biobank Inselspital Bern
  • Swiss National Science Foundation
  • SHCS research foundation
  • Young Talents in Clinical Research
  • program

Zitieren

APA

Begré, L., Boyd, A., Plissonnier, M. L., Testoni, B., Salazar-Vizcaya, L., Suter-Riniker, F., Scholtès, C., Béguelin, C., Rockstroh, J. K., Günthard, H. F., Calmy, A., Cavassini, M., Hirsch, H. H., Schmid, P., Bernasconi, E., Levrero, M., Wandeler, G., Zoulim, F., Rauch, A., & Swiss HIV Cohort Study (2024). Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiae189

Vancouver

Begré L, Boyd A, Plissonnier ML, Testoni B, Salazar-Vizcaya L, Suter-Riniker F, et al. Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy. The Journal of Infectious Diseases. 2024. doi:10.1093/infdis/jiae189

BibTeX
@article{Begr2024,
  author = {Begré, Lorin and Boyd, Anders and Plissonnier, Marie-Laure and Testoni, Barbara and Salazar-Vizcaya, Luisa and Suter-Riniker, Franziska and Scholtès, Caroline and Béguelin, Charles and Rockstroh, Jürgen K and Günthard, Huldrych F and Calmy, Alexandra and Cavassini, Matthias and Hirsch, Hans H and Schmid, Patrick and Bernasconi, Enos and Levrero, Massimo and Wandeler, Gilles and Zoulim, Fabien and Rauch, Andri and Swiss HIV Cohort Study, Swiss HIV Cohort Study},
  title = {Circulating HBV RNA and Hepatitis B Core–Related Antigen Trajectories in Persons With HIV/HBV Coinfection and Hepatitis B Surface Antigen Loss During Tenofovir Therapy},
  journal = {The Journal of Infectious Diseases},
  year = {2024},
  doi = {10.1093/infdis/jiae189}
}
Kostenlos starten →